多西他赛对比监测在高危前列腺癌根治术后的Ⅲ期随机试验
斯堪的纳维亚前列腺癌组12试验纳入459例根治术后高危前列腺癌患者,随机接受6周期多西他赛(75mg/m2,每3周)或监测。主要终点为PSA进展≥0.5ng/ml,5年进展风险多西他赛组45% vs 监测组38%,限制性平均生存时间差异无统计学意义(p=0.06)。结论:多西他赛未显著改善生化无病生存。
要点
- 根治术后高危前列腺癌患者中,6周期多西他赛未显著改善生化无病生存。
- 多西他赛组严重不良事件116例,监测组41例,无治疗相关死亡。
- 5年进展风险多西他赛组45%,监测组38%。
核心结论
- 多西他赛单药(不含激素治疗)未显著改善高危前列腺癌根治术后的生化无病生存。
研究设计与样本
- 开放标签、随机、多国Ⅲ期试验,纳入459例根治术后高危前列腺癌患者,1:1随机分配至6周期多西他赛75mg/m2每3周组或监测组。
主要发现
- 主要终点(PSA进展≥0.5ng/ml)在190/459例患者中达到,5年进展风险多西他赛组45%,监测组38%。
- 限制性平均生存时间多西他赛组43个月 vs 监测组46个月,差异3.2个月(95%CI:6.7至-1.5个月),p=0.06。
- 多西他赛组记录116例严重不良事件,监测组41例,无治疗相关死亡。
关键数值与推荐
- 高危定义:pT2切缘阳性或pT3a Gleason评分≥4+3,pT3b,或淋巴结阳性且Gleason评分≥3+4。
- 主要终点为PSA进展≥0.5ng/ml。
临床怎么用
- 高危前列腺癌根治术后不推荐常规使用多西他赛单药辅助治疗以改善生化无病生存。
局限性
- 并非所有患者按方案接受多西他赛。
- 终点为生化进展,部分患者在达到终点前接受了放疗。
- Kaplan-Meier分析提示非比例风险,故采用限制性平均生存时间差异作为主要效应估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant chemotherapy is standard treatment for other solid tumours, but to date has not proven effective in prostate cancer. OBJECTIVE: o evaluate whether six cycles of docetaxel alone improve biochemical disease-free survival after radical prostatectomy for high-risk prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomised multinational phase 3 trial. Enrolment of 459 patients after prostatectomy. INCLUSION CRITERIA: high-risk pT2 margin positive or pT3a Gleason score ≥4+3, pT3b, or lymph node positive disease Gleason score ≥3+4. Patients assigned (1:1) to either six cycles of adjuvant docetaxel 75mg/m2 every 3 wk without daily prednisone (Arm A) or surveillance (Arm B) until endpoint was reached. Primary endpoint was prostate-specific antigen progression ≥0.5 ng/ml. INTERVENTION: Docetaxel treatment after prostatectomy. RESULTS AND LIMITATIONS: Median time to progression, death, or last follow-up was 56.8 mo. Primary endpoint was reached in 190/459 patients-the risk of progression at 5 yr being 41% (45% in Arm A and 38% in Arm B). There was evidence of nonproportional hazards in Kaplan-Meier analysis, so we used the difference in restricted mean survival time as the primary estimate of effect. Restricted mean survival time to endpoint was 43 mo in Arm A versus 46 mo in Arm B (p=0.06), a nonsignificant difference of 3.2 mo (95% confidence interval: 6.7 to -1.5 mo). A total of 116 serious adverse events were recorded in Arm A and 41 in Arm B with no treatment-related deaths. Not all patients received docetaxel by protocol. The endpoint is biochemical progression and some patients received radiation treatment before the endpoint. CONCLUSIONS: Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy. PATIENT SUMMARY: In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostate cancer decreases the risk of a rising prostate-specific antigen. We found no benefit from docetaxel given after radical prostatectomy.
引用
- Ahlgren GM, Flodgren P, Tammela TLJ, et al. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. Eur Urol. 2018. PMID: 29395502. doi:10.1016/j.eururo.2018.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。